Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : ABBV crawled date : 2021 - 06 - 29 save search
Upadacitinib (RINVOQ®) Met the Primary and All Secondary Endpoints in the 52-Week Phase 3 Maintenance Study in Ulcerative Colitis Patients
Published: 2021-06-29 (Crawled : 20:00) - biospace.com/
ABBV | News | $164.91 0.15% 1.2M
|
Health Technology
|
| O: -0.31%
H: 0.09%
C: -0.31%
phase 3 ulcerative colitis
AbbVie’s Rinvoq Shows Promise as Maintenance Drug for Ulcerative Colitis
Published: 2021-06-29 (Crawled : 17:00) - biospace.com/
ABBV | News | $164.91 0.15% 1.2M
|
Health Technology
|
| O: -0.31%
H: 0.09%
C: -0.31%
drug ulcerative colitis
Age-related Macular Degeneration Market in Pharmaceutical Industry | Technavio
Published: 2021-06-29 (Crawled : 03:00) - prnewswire.com
ABBV | News | $164.91 0.15% 1.2M
|
Health Technology
|
| O: -0.31%
H: 0.09%
C: -0.31%
AMGN | $265.32 0.98% 550K
|
Health Technology
|
| O: 0.16%
H: 0.3%
C: -0.31%
macular market
Gainers vs Losers
| 79% | 21% |
Top 10 Gainers
AGBA | News | $1.22 205.0% 86M
|
Finance
EGOX | $0.0606 68.33% 250M
|
NVFY | $3.45 63.51% 20M
|
Consumer Durables
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
ZCMD | $1.86 28.28% 29M
|
Commercial Services
PAPL | $2.07 26.22% 550K
|
RWOD | $10.08 26.05% 5.6M
|
n/a
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
SRFM 4 | $0.6 21.29% 850K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.